Caspases and ROS-Dependent mechanism of action mediated by combination of WP 631 and epothilone B

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1261-1270

  Rogalska, Aneta ^a   Bukowska, Barbara ^a   Marczak, Agnieszka ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Epothilone B; Ovarian cancer; Synergism; WP 631

Indexed keywords

3', 3' N XYLENYLBIS (DAUNORUBICIN); CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; EPOTHILONE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 3',3' N XYLENYLBIS(DAUNORUBICIN); ANTINEOPLASTIC AGENT; DAUNORUBICIN; EPOTHILONE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMICAL STRUCTURE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; OVARIAN CANCER CELL LINE; QUANTITATIVE ASSAY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FEMALE; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DAUNORUBICIN; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; EPOTHILONES; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84911480502     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140608150807     Document Type: Article

References (48)

1. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev., 2006, 58, 621-681.
2. McGuire, W.P., Current status of taxane and platinum-based chemotherapy in ovarian cancer. J. Clin. Oncol., 2003, 21, 133s-135s.
3. Du Bois, A.; Luck, H.J.; Meier, W.; Adams, H.P.; Mobus, V.; Costa, S.; Bauknecht, T.; Richter, B.; Warm, M.; Schroder, W.; Olbricht, S.; Nitz, U.; Jackisch, C.; Emons, G.; Wagner, U.; Kuhn, W.; Pfisterer, J. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst., 2003, 95, 1320-1329.
4. Vasey, P.A.; Jayson, G.C.; Gordon, A.; Gabra, H.; Coleman, R.; Atkinson, R.; Parkin, D.; Paul, J.; Hay, A.; Kaye, S.B. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst., 2004, 96, 1682-1691.
5. Pignata, S.; Scambia, G.; Ferrandina, G.; Savarese, A.; Sorio, R.; Breda, E.; Gebbia, V.; Musso, P.; Frigerio, L.; Del Medico, P.; Lombardi, A.V.; Febbraro, A.; Scollo, P.; Ferro, A.; Tamberi, S.; Brandes, A.; Ravaioli, A.; Valerio, M.R.; Aitini, E.; Natale, D.; Scaltriti, L.; Greggi, S.; Pisano, C.; Lorusso, D.; Salutari, V.; Legge, F.; Di Maio, M.; Morabito, A.; Gallo, C.; Perrone, F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J. Clin. Oncol., 2011, 29, 3628-3635.
6. Patankar, N.A.; Pritchard, J.; Van Grinsven, M.; Osooly, M.; Bally, M.B. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: The influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clin. Cancer Res., 2013, 19, 865-877.
7. Pang, B.; Qiao, X.; Janssen, L.; Velds, A.; Groothuis, T.; Kerkhoven, R.; Nieuwland, M.; Ovaa, H.; Rottenberg, S.; Van Tellingen, O.; Janssen, J.; Huijgens, P.; Zwart, W.; Neefjes, J. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat. Commun., 2013, 4, 1908.
8. Tacar, O.; Sriamornsak, P.; Dass, C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol., 2013, 65, 157-170.
9. Prota, A.E.; Bargsten, K.; Zurwerra, D.; Field, J.J.; Diaz, J.F.; Altmann, K.H.; Steinmetz, M.O. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science, 2013, 339, 587-590.
10. Gehl, J.; Boesgaard, M.; Paaske, T.; Jensen, B.V.; Dombernowsky, P. Paclitaxel and doxorubicin in metastatic breast cancer. Semin. Oncol., 1996, 23, 35-38.
11. Julka, P.K.; Awasthy, B.S.; Sharma, D.N.; Gairola, M.; Rath, G.K. Paclitaxel-epirubicin in advanced breast cancer. J. Assoc. Phys. India, 1999, 47, 499-502.
12. Bruckner, H.W.; Cagnoni, P.J.; Lee, J.M.; Chesser, M.R.; Andreotii, P.E. A sequence of adriamycin and Taxol® infusion for refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol., 1994, 13, 276.
13. Ray-Coquard, I.; Bachelot, T.; Guastalla, J.P.; Levy, E.; Tigaud, J.D.; Vincent, P.; Dramais, D.; Assouline, D.; Pujade-Lauraine, E. Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecol. Oncol., 2003, 88, 351-357.
14. Marczak, A.; Bukowska, B.; Rogalska, A. WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells. Environ. Toxicol. Pharmacol., 2014, 37, 256-266.
15. Rogalska, A.; Gajek, A.; Szwed, M.; Jozwiak, Z.; Marczak, A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: A comparison with the effect of doxorubicin. Toxicol. In Vitro, 2011, 25, 1712-1720.
16. Rogalska, A.; Marczak, A.; Gajek, A.; Szwed, M.; Sliwinska, A.; Drzewoski, J.; Jozwiak, Z. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol. In Vitro, 2013a, 27, 239-249.
17. Brooks, T.A.; O'Loughlin, K.L.; Minderman, H.; Bundy, B.N.; Ford, L.A.; Vredenburg, M.R.; Bernacki, R.J.; Priebe, W.; Baer, M.R. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest. New Drugs, 2007, 25, 115-122.
18. Pritchard, J.R.; Bruno, P.M.; Gilbert, L.A.; Capron, K.L.; Lauffenburger, D.A.; Hemann, M.T. Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. U S A, 2013, 110, E170-179.
19. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean? Br. J. Pharmacol., 2004, 142, 231-255.
20. Hempel, S.L.; Buettner, G.R.; O'Malley, Y.Q.; Wessels, D.A.; Flaherty, D.M. Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: Comparison with 2',7'-dichlorodihydro-fluorescein diacetate, 5(and 6)-carboxy-2',7'-dichlorodihydro-fluorescein diacetate, and dihydrorhodamine 123. Free Radic. Biol. Med., 1999, 27, 146-159.
21. Chaoui, D.; Faussat, A.M.; Majdak, P.; Tang, R.; Perrot, J.Y.; Pasco, S.; Klein, C.; Marie, J.P.; Legrand, O. JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells. Cytometry B Clin. Cytom., 2006, 70, 189-196.
22. Villa, P.; Kaufmann, S.H.; Earnshaw, W.C. Caspases and caspase inhibitors. Trends Biochem. Sci., 1997, 22, 388-393.
23. Singh, N.P.; McCoy, M.T.; Tice, R.R.; Schneider, E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Ex. Cell Res., 1988, 175, 184-191.
24. Michałowicz, J. Pentachlorophenol and ist derivatives induce oxidative damage and morphological changes in human lymphocytes (in vitro). Arch. Toxicol., 2010, 84, 379-387.
25. Shi, P.; Wang, M.M.; Jiang, L.Y.; Liu, H.T.; Sun, J.Z. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression. Chin. Med. J. (Engl), 2008, 121, 1975-1979.
26. Du Bois, A.; Quinn, M.; Thigpen, T.; Vermorken, J.; Avall-Lundqvist, E.; Bookman, M.; Bowtell, D.; Brady, M.; Casado, A.; Cervantes, A.; Eisenhauer, E.; Friedlaender, M.; Fujiwara, K.; Grenman, S.; Guastalla, J.P.; Harper, P.; Hogberg, T.; Kaye, S.; Kitchener, H.; Kristensen, G.; Mannel, R.; Meier, W.; Miller, B.; Neijt, J.P.; Oza, A.; Ozols, R.; Parmar, M.; Pecorelli, S.; Pfisterer, J.; Poveda, A.; Provencher, D.; Pujade-Lauraine, E.; Randall, M.; Rochon, J.; Rustin, G.; Sagae, S.; Stehman, F.; Stuart, G.; Trimble, E.; Vasey, P.; Vergote, I.; Verheijen, R.; Wagner, U. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol., 2005, 16, Suppl 8, 87-812.
27. Lindemann, K.; Christensen, R.D.; Vergote, I.; Stuart, G.; Izquierdo, M.A.; Kaern, J.; Havsteen, H.; Eisenhauer, E.; Ridderheim, M.; Lopez, A.B.; Hirte, H.; Aavall-Lundquvist, E.; Vrdoljak, E.; Green, J.; Kristensen, G.B. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann. Oncol., 2012, 23, 2613-2619.
28. Tennekes, H.A.; Sanchez-Bayo, F. The molecular basis of simple relationships between exposure concentration and toxic effects with time. Toxicology, 2013, 309, 39-51.
29. Choi, Y.K.; Cho, S.G.; Choi, H.S.; Woo, S.M.; Yun, Y.J.; Shin, Y.C.; Ko, S.G. JNK1/2 Activation by an Extract from the Roots of Morus alba L. Reduces the Viability of Multidrug-Resistant MCF-7/Dox Cells by Inhibiting YB-1-Dependent MDR1 Expression. Evid. Based Complement. Alternat. Med., 2013, 741-985.
30. Wang, X.; Wu, E.; Wu, J.; Wang, T.L.; Hsieh, H.P.; Liu, X. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. PloS One, 2013, 8, e65686.
31. Huang, S.; Bijangi-Vishehsaraei, K.; Saadatzadeh, M.R.; Safa, A.R. Human GM3 synthase attenuates taxol-triggered apoptosis associated with downregulation of caspase-3 in ovarian cancer cells. J. Cancer Ther., 2012, 3, 504-510.
32. Rogalska, A.; Szula, E.; Gajek, A.; Marczak, A.; Jozwiak, Z. Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B. Environ. Toxicol. Pharmacol., 2013b, 36, 600-610.
33. Minotti, G.; Saponiero, A.; Licata, S.; Menna, P.; Calafiore, A.M.; Teodori, G.; Gianni, L. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin. Cancer Res., 2001, 7, 1511-1515.
34. Zhou, Q.; Li, Y.; Jin, J.; Lang, L.; Zhu, Z.; Fang, W.; Chen, X. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo. Biol. Pharm. Bull., 2012, 35, 2170-2179.
35. Jakubowicz-Gil, J.; Langner, E.; Badziul, D.; Wertel, I.; Rzeski, W. Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. Tumour Biol., 2012, 34, 2367-2378.
36. Liu, J.R.; Opipari, A.W.; Tan, L.; Jiang, Y.; Zhang, Y.; Tang, H.; Nunez, G. Dysfunctional apoptosome activation in ovarian cancer: Implications for chemoresistance. Cancer Res., 2002, 62, 924-931.
37. Lu, C.; Shao, C.; Cobos, E.; Singh, K.P.; Gao, W. Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PloS One, 2012, 7, e32895.
38. Taylor, D.J.; Parsons, C.E.; Han, H.; Jayaraman, A.; Rege, K. Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer, 2011, 11, 470.
39. Siddiqui-Jain, A.; Bliesath, J.; Macalino, D.; Omori, M.; Huser, N.; Streiner, N.; Ho, C.B.; Anderes, K.; Proffitt, C.; O'Brien, S.E.; Lim, J.K.; Von Hoff, D.D.; Ryckman, D.M.; Rice, W.G.; Drygin, D. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: Mechanistic rationale for drug combination therapy. Mol. Cancer Ther., 2012, 11, 994-1005.
40. Wiltshire, T.; Senft, J.; Wang, Y.; Konat, G.W.; Wenger, S.L.; Reed, E.; Wang, W. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Mol. Pharmacol., 2007, 71, 1051-1060.
41. Blagosklonny, M.V.; Robey, R.; Bates, S.; Fojo, T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J. Clin. Invest., 2000, 105, 533-539.
42. Lee, H.H.; Ye, S.; Li, X.J.; Lee, K.B.; Park, M.H.; Kim, S.M. Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt. Oncol. Rep., 2014, 31, 183-188.
43. Ajabnoor, G.M.; Crook, T.; Coley, H.M. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis., 2012, 3, e260.
44. Nagaria, P.; Robert, C.; Rassool, F.V. DNA double-strand break response in stem cells: Mechanisms to maintain genomic integrity. Biochim. Biophys. Acta, 2013, 1830, 2345-2353.
45. Baumgart, T.; Klautke, G.; Kriesen, S.; Kuznetsov, S.A.; Weiss, D.G.; Fietkau, R.; Hildebrandt, G.; Manda, K. Radiosensitizing effect of epothilone B on human epithelial cancer cells. Strahlenther Onkol, 2012, 188, 177-184.
46. Pozarowski, P.; Huang, X.; Gong, R.W.; Priebe, W.; Darzynkiewicz, Z. Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: Effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. Cytometry A, 2004, 57, 113-119.
47. Portugal, J.; Cashman, D.J.; Trent, J.O.; Ferrer-Miralles, N.; Przewloka, T.; Fokt, I.; Priebe, W.; Chaires, J.B. A new bisintercalating anthracycline with picomolar DNA binding affinity. J. Med. Chem., 2005, 48, 8209-8219.
48. Villamarin, S.; Ferrer-Miralles, N.; Mansilla, S.; Priebe, W.; Portugal, J. Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem. Pharmacol., 2002, 63, 1251-1258.